CPJE PAIN MANAGEMENT MASTERY
200 CLINICAL QUESTIONS WITH
DETAILED RATIONALES
CALIFORNIA PHARMACY LAW AND
OPIOID PRESCRIBING BOARD EXAM
PREP
1. A 68-year-old male with chronic low back pain secondary to
degenerative disc disease is currently taking oxycodone IR 10 mg every 6
hours around-the-clock. His pain remains inadequately controlled at
7/10, and he reports breakthrough pain episodes 3-4 times daily. The
prescriber is considering transitioning him to a long-acting opioid
formulation. Which of the following represents the most appropriate
total daily dose conversion when switching from immediate-release
oxycodone to extended-release oxycodone, while adhering to opioid
conversion safety guidelines that recommend dose reduction for
incomplete cross-tolerance?
A) Oxycodone ER 40 mg every 12 hours
B) Oxycodone ER 30 mg every 12 hours
C) Oxycodone ER 20 mg every 12 hours
D) Oxycodone ER 15 mg every 12 hours
E) Oxycodone ER 60 mg once daily
Rationale: The patient is currently taking oxycodone IR 10 mg Q6H = 40
mg total daily dose. When converting to extended-release formulations,
the total daily dose should initially be equivalent, but guidelines
recommend reducing the calculated equianalgesic dose by 25-50% to
account for incomplete cross-tolerance between formulations and reduce
overdose risk. Therefore, 40 mg reduced by 25-50% yields 20-30 mg
total daily; starting conservatively at 20 mg TDD (10 mg Q12H) or 30 mg
TDD (15 mg Q12H) is appropriate, with 20 mg Q12H being the most
conservative and safest initial choice among options provided.
2. A 55-year-old female with diabetic peripheral neuropathy presents
with burning, tingling pain in her feet rated 6/10 that worsens at night.
,She has tried acetaminophen and ibuprofen with minimal relief. Her
medical history includes type 2 diabetes, hypertension, and mild chronic
kidney disease (eGFR 45 mL/min/1.73m²). Which of the following
pharmacologic agents is considered first-line therapy for neuropathic
pain in this patient and requires the LEAST dose adjustment given her
renal function?
A) Pregabalin 75 mg twice daily
B) Gabapentin 300 mg three times daily
C) Duloxetine 30 mg once daily
D) Amitriptyline 25 mg at bedtime
E) Tramadol 50 mg every 6 hours as needed
Rationale: Duloxetine, an SNRI, is FDA-approved for diabetic peripheral
neuropathic pain and is considered first-line therapy per multiple
guidelines. Unlike pregabalin and gabapentin, which require significant
dose reduction in renal impairment (eGFR <60), duloxetine does not
require dosage adjustment in mild-to-moderate renal impairment.
Amitriptyline carries significant anticholinergic and cardiac risks,
especially in older adults. Tramadol requires caution in renal
impairment and carries seizure and serotonin syndrome risks.
3. A pharmacist receives a prescription for fentanyl transdermal system
25 mcg/hour applied every 72 hours for a patient with chronic cancer-
related pain. The patient's current regimen includes morphine sulfate ER
30 mg every 12 hours. When counseling this patient on the appropriate
use of the fentanyl patch, which of the following statements is MOST
critical to prevent a potentially fatal medication error?
A) "Apply the patch to a hairy area of the upper arm to ensure better
adhesion."
B) "You may cut the patch in half if you experience excessive sedation."
C) "Do not expose the application site or patch to direct heat sources
such as heating pads, electric blankets, or hot tubs."
D) "Remove the old patch and immediately apply the new one to the
exact same location."
E) "Dispose of used patches by flushing them down the toilet to prevent
accidental exposure."
,Rationale: External heat sources increase skin blood flow and
dramatically accelerate fentanyl absorption from transdermal systems,
potentially causing fatal respiratory depression. This is a critical safety
counseling point. Patches should NOT be cut (alters drug release
kinetics), should be applied to non-hairy, intact skin on upper
torso/upper arm, rotated to different sites, and disposed of via drug
take-back programs or folding sticky sides together before discarding in
household trash per FDA guidelines—not flushed unless specifically on
the FDA flush list (fentanyl patches ARE on this list, but heat exposure
remains the most critical immediate safety counseling point for patient
use).
4. A 72-year-old male with osteoarthritis of the knees and a history of
peptic ulcer disease (treated and healed) presents with moderate pain
rated 5/10. He is currently taking low-dose aspirin 81 mg daily for
cardiovascular prophylaxis. Which of the following analgesic regimens
presents the LOWEST risk of gastrointestinal complications while
providing effective pain relief?
A) Naproxen 500 mg twice daily with omeprazole 20 mg daily
B) Celecoxib 200 mg once daily
C) Acetaminophen 1000 mg three times daily scheduled
D) Ibuprofen 800 mg three times daily as needed
E) Diclofenac sodium topical gel 1% applied to knees four times daily
Rationale: Acetaminophen is first-line for osteoarthritis pain per ACR
and OARSI guidelines, especially in patients with GI risk factors. It lacks
antiplatelet effects and does not increase GI bleeding risk like NSAIDs.
While celecoxib (a COX-2 selective NSAID) has lower GI risk than non-
selective NSAIDs, it still carries some risk and cardiovascular concerns.
Topical diclofenac is also a good option with minimal systemic
absorption, but acetaminophen remains the safest initial choice in a
patient with prior PUD on aspirin. Scheduled dosing optimizes efficacy
for chronic pain.
5. A patient receiving morphine patient-controlled analgesia (PCA)
postoperatively becomes excessively sedated with a respiratory rate of 8
breaths/minute and pinpoint pupils. Naloxone is ordered for reversal.
Which of the following naloxone dosing strategies is MOST appropriate
, to reverse respiratory depression while minimizing the risk of
precipitating acute withdrawal and severe pain recurrence?
A) Administer naloxone 2 mg IV push immediately, repeat every 2
minutes until alert
B) Dilute naloxone 0.4 mg in 10 mL normal saline and administer 1 mL
(0.04 mg) IV every 2-3 minutes titrated to adequate respiration
C) Administer naloxone 0.4 mg IM once and monitor
D) Administer naloxone 4 mg intranasally as a single dose
E) Withhold naloxone and provide ventilatory support only
Rationale: In opioid-dependent patients or those on chronic opioids,
rapid full reversal with high-dose naloxone can precipitate severe acute
withdrawal, hypertension, tachycardia, pulmonary edema, and
uncontrolled pain. Titration with diluted naloxone (0.04 mg increments)
allows reversal of life-threatening respiratory depression while
preserving some analgesia and minimizing withdrawal. IV route allows
precise titration. Intranasal 4 mg is appropriate for community overdose
reversal but not ideal for controlled hospital titration.
6. A 45-year-old female with fibromyalgia is prescribed milnacipran for
pain management. The pharmacist notes she is also taking tramadol for
breakthrough pain and sertraline for depression. Which of the following
adverse effects represents the MOST significant concern with this
medication combination?
A) Hypertensive crisis
B) Serotonin syndrome
C) QTc prolongation
D) Hepatotoxicity
E) Seizure activity
Rationale: Milnacipran (an SNRI), tramadol (weak mu-agonist with
SNRI properties), and sertraline (SSRI) all increase serotonergic activity.
Combining multiple serotonergic agents significantly increases the risk
of serotonin syndrome, characterized by mental status changes,
autonomic hyperactivity, and neuromuscular abnormalities. This is a
potentially life-threatening interaction requiring careful monitoring and
patient education on symptoms. While tramadol alone lowers seizure
200 CLINICAL QUESTIONS WITH
DETAILED RATIONALES
CALIFORNIA PHARMACY LAW AND
OPIOID PRESCRIBING BOARD EXAM
PREP
1. A 68-year-old male with chronic low back pain secondary to
degenerative disc disease is currently taking oxycodone IR 10 mg every 6
hours around-the-clock. His pain remains inadequately controlled at
7/10, and he reports breakthrough pain episodes 3-4 times daily. The
prescriber is considering transitioning him to a long-acting opioid
formulation. Which of the following represents the most appropriate
total daily dose conversion when switching from immediate-release
oxycodone to extended-release oxycodone, while adhering to opioid
conversion safety guidelines that recommend dose reduction for
incomplete cross-tolerance?
A) Oxycodone ER 40 mg every 12 hours
B) Oxycodone ER 30 mg every 12 hours
C) Oxycodone ER 20 mg every 12 hours
D) Oxycodone ER 15 mg every 12 hours
E) Oxycodone ER 60 mg once daily
Rationale: The patient is currently taking oxycodone IR 10 mg Q6H = 40
mg total daily dose. When converting to extended-release formulations,
the total daily dose should initially be equivalent, but guidelines
recommend reducing the calculated equianalgesic dose by 25-50% to
account for incomplete cross-tolerance between formulations and reduce
overdose risk. Therefore, 40 mg reduced by 25-50% yields 20-30 mg
total daily; starting conservatively at 20 mg TDD (10 mg Q12H) or 30 mg
TDD (15 mg Q12H) is appropriate, with 20 mg Q12H being the most
conservative and safest initial choice among options provided.
2. A 55-year-old female with diabetic peripheral neuropathy presents
with burning, tingling pain in her feet rated 6/10 that worsens at night.
,She has tried acetaminophen and ibuprofen with minimal relief. Her
medical history includes type 2 diabetes, hypertension, and mild chronic
kidney disease (eGFR 45 mL/min/1.73m²). Which of the following
pharmacologic agents is considered first-line therapy for neuropathic
pain in this patient and requires the LEAST dose adjustment given her
renal function?
A) Pregabalin 75 mg twice daily
B) Gabapentin 300 mg three times daily
C) Duloxetine 30 mg once daily
D) Amitriptyline 25 mg at bedtime
E) Tramadol 50 mg every 6 hours as needed
Rationale: Duloxetine, an SNRI, is FDA-approved for diabetic peripheral
neuropathic pain and is considered first-line therapy per multiple
guidelines. Unlike pregabalin and gabapentin, which require significant
dose reduction in renal impairment (eGFR <60), duloxetine does not
require dosage adjustment in mild-to-moderate renal impairment.
Amitriptyline carries significant anticholinergic and cardiac risks,
especially in older adults. Tramadol requires caution in renal
impairment and carries seizure and serotonin syndrome risks.
3. A pharmacist receives a prescription for fentanyl transdermal system
25 mcg/hour applied every 72 hours for a patient with chronic cancer-
related pain. The patient's current regimen includes morphine sulfate ER
30 mg every 12 hours. When counseling this patient on the appropriate
use of the fentanyl patch, which of the following statements is MOST
critical to prevent a potentially fatal medication error?
A) "Apply the patch to a hairy area of the upper arm to ensure better
adhesion."
B) "You may cut the patch in half if you experience excessive sedation."
C) "Do not expose the application site or patch to direct heat sources
such as heating pads, electric blankets, or hot tubs."
D) "Remove the old patch and immediately apply the new one to the
exact same location."
E) "Dispose of used patches by flushing them down the toilet to prevent
accidental exposure."
,Rationale: External heat sources increase skin blood flow and
dramatically accelerate fentanyl absorption from transdermal systems,
potentially causing fatal respiratory depression. This is a critical safety
counseling point. Patches should NOT be cut (alters drug release
kinetics), should be applied to non-hairy, intact skin on upper
torso/upper arm, rotated to different sites, and disposed of via drug
take-back programs or folding sticky sides together before discarding in
household trash per FDA guidelines—not flushed unless specifically on
the FDA flush list (fentanyl patches ARE on this list, but heat exposure
remains the most critical immediate safety counseling point for patient
use).
4. A 72-year-old male with osteoarthritis of the knees and a history of
peptic ulcer disease (treated and healed) presents with moderate pain
rated 5/10. He is currently taking low-dose aspirin 81 mg daily for
cardiovascular prophylaxis. Which of the following analgesic regimens
presents the LOWEST risk of gastrointestinal complications while
providing effective pain relief?
A) Naproxen 500 mg twice daily with omeprazole 20 mg daily
B) Celecoxib 200 mg once daily
C) Acetaminophen 1000 mg three times daily scheduled
D) Ibuprofen 800 mg three times daily as needed
E) Diclofenac sodium topical gel 1% applied to knees four times daily
Rationale: Acetaminophen is first-line for osteoarthritis pain per ACR
and OARSI guidelines, especially in patients with GI risk factors. It lacks
antiplatelet effects and does not increase GI bleeding risk like NSAIDs.
While celecoxib (a COX-2 selective NSAID) has lower GI risk than non-
selective NSAIDs, it still carries some risk and cardiovascular concerns.
Topical diclofenac is also a good option with minimal systemic
absorption, but acetaminophen remains the safest initial choice in a
patient with prior PUD on aspirin. Scheduled dosing optimizes efficacy
for chronic pain.
5. A patient receiving morphine patient-controlled analgesia (PCA)
postoperatively becomes excessively sedated with a respiratory rate of 8
breaths/minute and pinpoint pupils. Naloxone is ordered for reversal.
Which of the following naloxone dosing strategies is MOST appropriate
, to reverse respiratory depression while minimizing the risk of
precipitating acute withdrawal and severe pain recurrence?
A) Administer naloxone 2 mg IV push immediately, repeat every 2
minutes until alert
B) Dilute naloxone 0.4 mg in 10 mL normal saline and administer 1 mL
(0.04 mg) IV every 2-3 minutes titrated to adequate respiration
C) Administer naloxone 0.4 mg IM once and monitor
D) Administer naloxone 4 mg intranasally as a single dose
E) Withhold naloxone and provide ventilatory support only
Rationale: In opioid-dependent patients or those on chronic opioids,
rapid full reversal with high-dose naloxone can precipitate severe acute
withdrawal, hypertension, tachycardia, pulmonary edema, and
uncontrolled pain. Titration with diluted naloxone (0.04 mg increments)
allows reversal of life-threatening respiratory depression while
preserving some analgesia and minimizing withdrawal. IV route allows
precise titration. Intranasal 4 mg is appropriate for community overdose
reversal but not ideal for controlled hospital titration.
6. A 45-year-old female with fibromyalgia is prescribed milnacipran for
pain management. The pharmacist notes she is also taking tramadol for
breakthrough pain and sertraline for depression. Which of the following
adverse effects represents the MOST significant concern with this
medication combination?
A) Hypertensive crisis
B) Serotonin syndrome
C) QTc prolongation
D) Hepatotoxicity
E) Seizure activity
Rationale: Milnacipran (an SNRI), tramadol (weak mu-agonist with
SNRI properties), and sertraline (SSRI) all increase serotonergic activity.
Combining multiple serotonergic agents significantly increases the risk
of serotonin syndrome, characterized by mental status changes,
autonomic hyperactivity, and neuromuscular abnormalities. This is a
potentially life-threatening interaction requiring careful monitoring and
patient education on symptoms. While tramadol alone lowers seizure
